Patent ID: 6974833

Claim:
A method for treatment of a collagenase-linked degenerative disease in a mammal in need thereof comprising administering to the mammal a therapeutic effective amount of a composition comprising: i) at least one collagen synthesis activator selected from the group consisting of ascorbyl ε-aminocaproate, and ascorbyl aminomethylcyclohexane carboxylic acid; ii) at least one fibrinolytic inhibitor selected from the group consisting of ε-aminocaproic acid, tranexamic acid, p-aminomethylbenzoic acid, p-benzylamine sulfuric acid, α-N-acetyl-lysine-methyl ester, cis/trans-4-aminomethylcyclohexane carboxylic acid, trans-4-aminomethycyclohexane carboxylic acid, 4-aminomethyl-bicyclo-2,2.2-octane carboxylic acid, natural lysine and proline; iii) at least one anti-oxidant selected from the group consisting of tocopherol, carotene and N-acetyl cysteine, selenium, and probucol; and iv) a pharmaceutically acceptable carrier, wherein the i)-iv) ingredients of the composition function to inhibit extracellular matrix degradation and stimulate collagen synthesis so as to treat the collagenase-linked degenerative disease.